Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

23.43B

Market cap23.43B

Price-Earnings ratio

16.58

Price-Earnings ratio16.58

Dividend yield

—

Dividend yield—

Average volume

2.01M

Average volume2.01M

High today

$118.51

High today$118.51

Low today

$118.51

Low today$118.51

Open price

$118.00

Open price$118.00

Volume

1.28K

Volume1.28K

52 Week high

$118.77

52 Week high$118.77

52 Week low

$67.17

52 Week low$67.17

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $118.51. The company's market cap stands at 23.43B, with a P/E ratio of 16.58.

During the trading session on 2026-07-09, Incyte(INCY) shares reached a daily high of $118.51 and a low of $118.51. At a current price of $118.51, the stock is 0.0% higher than the low and still 0.0% under the high.

Trading activity shows a volume of 1.28K, compared to an average daily volume of 2.01M.

The stock's 52-week range extends from a low of $67.17 to a high of $118.77.

INCY News

Investing.com 22h

Incyte stock hits 52-week high at 118.77 USD - Investing.com

...

TipRanks 2d

Incyte price target raised to $99 from $95 at RBC Capital

RBC Capital raised the firm’s price target on Incyte (INCY) to $99 from $95 and keeps a Sector Perform rating on the shares as part of a broader research note p...

TipRanks 3d

Incyte Acquires Vega Therapeutics, Expands Hematology Pipeline

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Analyst ratings

55%

of 29 ratings

Buy

41.4%

Hold

55.2%

Sell

3.4%

More INCY News

TipRanks 3d

Incyte completes acquisition of Vega Therapeutics

Incyte (INCY) completed its acquisition of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics. The acquisition adds VGA039, a novel monoclonal an...

Simply Wall St 4d

Incyte On Opzelura Progress And Strong Revenue Has Valuation Back In Focus

Incyte (INCY) has been in focus after a series of events, including a favorable US$246 million Medicaid settlement tied to Opzelura and a positive European opin...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.